- Vertex Pharmaceuticals (NASDAQ:VRTX) announces that reimbursement has been established in Australia for cystic fibrosis med Symdeko (tezacaftor/ivacaftor and ivacaftor) for patients at least 12 years old who are homozygous for the F508del mutation or who have one copy of the F505del mutation and another responsive residual function mutation in the CFTR gene.
- The company says its cystic fibrosis medicines are reimbursed in 17 countries around the world.
Vertex's Symdeko nabs reimbursement in Australia
Recommended For You
More Trending News
About VRTX Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
VRTX | - | - |
Vertex Pharmaceuticals Incorporated |